US EditionOzempic Patent Arrives at the End of the Morning: What Changes Now in Brazil
4 Articles
4 Articles
The patent of semagglutide, the active principle of Ozempic, Wegovy and Rybelsus, medicinal products indicated for the treatment of diabetes and obesity come to an end this Saturday (20). This means that generic and similar medicinal products can be marketed in Brazil since the Anvisa approved. According to Brazilian legislation, innovative medicines, such as Ozempic, can be protected by patents. The period guaranteed by pharmacies - in the case…
The owner of the original patent loses control in India, China and other nations.They represent 40% of the planet and begin to manufacture generic semaglutide there.It coincides with the dissemination of an unpublished volume of adverse effects reports.
See the main newspapers and booklets of the day in Brazil and the world. Read texts and watch videos of Politics, Citidian, Crimes and more.
The patent of semaglutide opens the global market to a richer, cheaper gene, while new studies warn of risks so far little widespread.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
